HMBeacon: A Phase 2 Study to Evaluate ALN-6400 in Adult and Adolescent Female Patients With VWD and HMB

Clinical trial NCT07575308 · RECRUITING

Trial details

NCT number: NCT07575308
Sponsor: Alnylam Pharmaceuticals
Status: RECRUITING
Phase: Phase 2
Study type: INTERVENTIONAL

Von Willebrand Disease (VWD)Heavy Menstrual Bleeding (HMB)

Start date: 2026-07-30
Primary completion: 2027-06-30
Enrollment: 24

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.